Merck accelerates cuts to U.S. sales force
Merck is cutting 1,200 U.S. sales positions as it transitions to a new commercial model, the company announces May 5. The action is an acceleration of planned efficiencies under its "Plan to Win" cost-savings program, announced in 2005, the firm said (1"The Pink Sheet" Dec. 19, 2005, p. 3). With the most recent lay offs, Merck will have eliminated 1,600 positions, or 20 percent, of its sales force
You may also be interested in...
Merck's restructuring program is shifting selling and marketing resources away from physician detailing towards payer and patient promotion, CEO Richard Clark indicated during the firm's annual business review in Whitehouse Station, N.J
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker